Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Sirolimus as primary immunosuppression is effective in attenuating progression of cardiac-allograft vasculopathy

Nature Clinical Practice Cardiovascular Medicine volume 5, pages 300–301 (2008)Cite this article

Raichlin E et al. (2007) Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation 116: 2726–2733

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Taylor DO et al. (2007) Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report—2007. J Heart Lung Transplant 26: 769–781

    Article  Google Scholar 

  2. Eisen HJ et al. (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349: 847–858

    Article  CAS  Google Scholar 

  3. Stallone G et al. (2005) Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352: 1317–1323

    Article  CAS  Google Scholar 

  4. Sayegh MH and Remuzzi G (2007) Clinical update: immunosuppression minimisation. Lancet 369: 1676–1678

    Article  Google Scholar 

  5. Hunt J et al (2007) Premature termination of a prospective, open label, randomized, multicenter study of sirolimus to replace calcineurin inhibitors (CNI) in a standard care regimen of CNI, MMF and corticosteroids early after heart transplantation. J Heart Lung Transplant 26 (Suppl 2): 398

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rodolfo Medina, Research Editor, Nature Clinical Practice.

Author information

Author notes

  1. Massachusetts General Hospital, Department of Surgery, Cox 654, 55 Fruit Street, Boston, MA 02114, USA madsen@helix.mgh.harvard.edu

Authors and Affiliations

  1. JC Madsen is the Director of the MGH Transplant Center and the W Gerald and Patricia R Austen Distinguished Scholar in Cardiac Surgery at Massachusetts General Hospital, Boston, MA, USA.,

    Joren C Madsen

Authors
  1. Joren C Madsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Madsen, J. Sirolimus as primary immunosuppression is effective in attenuating progression of cardiac-allograft vasculopathy. Nat Rev Cardiol 5, 300–301 (2008). https://doi.org/10.1038/ncpcardio1213

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio1213

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing